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OBJECTIVE:
 
 The Minimum Data Set (MDS) is an inter-
national facility-reported database used to standardize
the assessment process and improve the quality of care in
nursing homes. Specific MDS assessments are used as
quality indicators to determine the prevalence of antipsy-
chotic prescribing as well as potentially inappropriate anti-
psychotic usage. MDS classifies low-risk residents as receiv-
ing an antipsychotic medication but having no documented
psychotic or related condition and no cognitive impairment
with behavioral symptoms. Without an audit of resident
records, it is impossible to determine if the MDS accurately
reports the prevalence of antipsychotic medications and
whether all low-risk residents represent inappropriate
prescribing. The purpose of this study was to deter-
mine MDS validity for identifying low-risk residents in
Texas.
METHODS: Facility-based MDS assessments were com-
pared to independent on-site assessments. A team of
pharmacists reviewed the chart records of low risk resi-
dents and determined whether a resident received an an-
tipsychotic medication and the presence or absence of a
valid indication. These findings were compared to the
statewide MDS quality indicator prevalence rate.
RESULTS: Based on MDS assessments, 10,163 residents
from 1021 nursing homes were identified as low risk.
The chart records revealed that 12.4% of these residents
were not receiving antipsychotic medication. Of the 8904
residents who were receiving an antipsychotic, 48.2%
had a valid diagnosis or indication and were mistakenly
identified as low-risk by the MDS database. Of the re-
maining 4610 residents, 84.4% were missing a diagnosis
and 15.6% had an inappropriate indication.
CONCLUSION: For this population of residents, a lack
of accurate essential diagnostic information in MDS as-
sessments and a high prevalence of inappropriate antipsy-
chotic prescribing was found to be a widespread prob-
lem. These findings indicate that nursing facilities were
inaccurate in their responses to MDS assessment items
and therefore, the MDS had poor validity as a quality in-
dicator for antipsychotic use.
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OBJECTIVE:
 
 Practice guidelines are being implemented
for many diseases to improve outcomes, increase use of
evidence-based medicine, and to reduce medical errors.
Rarely are these efforts systematically evaluated in clini-
cal care. We chose breast cancer in women as one disease
that has excellent scientific evidence on treatment efficacy
but almost no data on actual use in physician practice.
METHODS: We studied use of breast conserving sur-
gery, breast reconstruction, adjuvant chemotherapy, radi-
ation, taxoids, tamoxifen, and aromatase inhibitors in el-
igible women. The population was diagnosed between
1995 and 2000 in six surgical oncology practices in the
eight counties around Philadelphia with nearly seven mil-
lion people. Four thousand three hundred ninety five
women were enrolled and followed retrospectively up to
five years after diagnosis. We abstracted each patient’s
complete clinical record.
RESULTS: Lumpectomy was provided to 51.0% of
women, among whom 2.3% also had reconstruction.
Forty nine percent of women (49.0%) had mastectomy
with 18.0% having breast reconstruction, 56.8% re-
ceived radiation therapy and 32.3% received adjuvant
chemotherapy. Among eligible women, 0.6% had aro-
matase inhibitors and 12.3% were prescribed taxoids.
Among estrogen and/or progesterone-receptor-positive
women, 72.4% got tamoxifen, while 35.1% with nega-
tive estrogen and progesterone receptors got tamoxifen.
One woman refused all treatment, one refused any breast
surgery, five refused adjuvant chemotherapy, two refused
radiation. Eight percent of eligible women refused tamox-
ifen, mainly because of elevated risk of adverse side effects,
and one had an autologous bone marrow transplant. Lo-
gistic regression found that breast reconstruction was in-
